Medicare Prescription Payment Plan (MPPP): Awareness, utilization, and barriers among people with cancer.
Abstract
175 Background: MPPP allows people with Medicare prescription drug coverage (Part D) to spread drug costs over the year. Given high costs of many cancer prescription drugs, patients may benefit from smaller monthly payments rather than large upfront costs. Despite potential to reduce financial burden and access barriers, MPPP uptake depends on patient awareness and understanding. We examined MPPP awareness, utilization, and participation barriers among Medicare beneficiaries with cancer. Methods: Cancer Care conducted a national cross-sectional survey (Feb-Apr 2026). Respondents were recruited via email using Cancer Care client lists (people who sought financial, practical, or other support). Questions included MPPP awareness/enrollment experiences and socio-demographics. Descriptive and logistic regression analyses characterized responses and awareness correlates. Results: Analyses included 215 cancer patients with Medicare Part D (67% women, 79% age 65+, 70% White, 40% married, 15% ≤HS diploma, 58% HH income <$50K, 49% Medicare Advantage, 27% Low Income Subsidy, 16% found cancer prescriptions “very hard” to afford, 46% treated at academic/comprehensive center). MPPP awareness was low: only 34% had heard of MPPP, and just 6% had enrolled. In logistic regression, higher education (OR=3.72, CI 1.31-10.59, p=.014), being married (OR=2.42, CI 1.30-4.51, p=.005), and finding it “very hard” to afford prescriptions for cancer (OR=3.51, CI 1.58-7.76, p=.002) were associated with awareness. Nearly half (46%) said receiving MPPP information from their healthcare team would be quite a bit/very helpful. Among those aware ( n =74), most learned of MPPP from Medicare (36%) or their health/drug plan (30%), and only 9% from physician/nurse/PA, 8% pharmacist, 3% social worker/financial counselor. 42% of aware respondents lacked sufficient information to determine whether MPPP could help them. Only 14% knew how to enroll in MPPP; the most common barrier among non-enrollees ( n =202) was lack of MPPP awareness (43%). Top motivators for future enrollment included knowing MPPP has no fees/interest (39%), knowing MPPP does not affect drug coverage (33%), and education from the healthcare team (33%). After reading a brief explanation, 40% reported that MPPP could be at least somewhat helpful to them, and 20% were somewhat-to-very likely to enroll. Conclusions: MPPP awareness and uptake are critically low among surveyed cancer patients with Medicare Part D. While MPPP may not benefit everyone, awareness gaps can compromise informed decisions on cost management and medication access. Awareness came most often via Medicare and health plan communications, yet many wanted MPPP information from their healthcare team. Findings highlight an urgent role for insurance plans, healthcare and pharmacy teams, and patient advocacy groups in building MPPP awareness and equipping patients to make informed decisions.